menu
    • menu
    [{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"NNI-362","moa":"Allosteric p70S6 kinase","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NNI-362","moa":"Allosteric p70S6 kinase","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NNI-351","moa":"DYRK kinase","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Neuronascent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuronascent \/ Not Applicable"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Neuronascent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Neuronascent

    Menu

    Neuronascent

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

                            Details : NNI-362, Neuronascent’s lead, patented, new chemical entity, was developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegeneration.

                            Brand Name : NNI-362

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 08, 2022

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NNI-351

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome

                            Details : NNI-351 is Neuronascent’s lead, patented, new chemical entity aimed at reversing developmental disorders by producing new neurons postnatally to enhance neurogenesis that is slowed during early development in diseases such as FXS.

                            Brand Name : NNI-351

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2022

                            Lead Product(s) : NNI-351

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institute on Aging

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimers Diseas...

                            Details : NNI-362, at the two multi-doses, 120 mg and 240 mg, was shown to significantly reduce p-tau181 levels versus pre-treatment levels in study participants, also showed a significant reduction of an Alzheimer’s disease pathological biomarker.

                            Brand Name : NNI-362

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2022

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Aging

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Neuronascent

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institute on Aging

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer’s Disease

                            Details : NNI-362 is Neuronascent's lead, patented, new chemical entity developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegenerative disorders.

                            Brand Name : NNI-362

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 29, 2021

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Aging

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth